Skip to content
Medical Health Aged Care

Menicon’s Largest Malaysia Plant Begins Commercial Production

Menicon Co., Ltd. 2 mins read

- Strengthening Global Production Capacity for the Rapidly Growing 1-Day Lens Market


NAGOYA, Japan--BUSINESS WIRE--

Menicon Co., Ltd. is pleased to announce that its new manufacturing facility in Kedah, Malaysia, has commenced commercial production. The plant strengthens Menicon’s long-standing commitment to technological excellence, uncompromising quality, and a stable global supply of contact lenses.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127294120/en/

The newly opened Malaysia plant is Menicon’s largest site to date and is dedicated exclusively to producing 1-DAY lenses.
As global demand for 1-DAY lenses continues rising and the industry faces widespread supply constraints, Menicon has made significant capital investments to expand production capacity—even amid the uncertainties presented by the COVID-19 pandemic.
Construction of phase 1, currently underway, will provide capacity for up to 500 million lenses per year. The construction plan is strategically formulated to extend through phase 4, allowing for further expansion in response to future market demand. With the continued installation of additional production lines, the company envisions a system capable of producing up to 2 billion lenses annually in the future.

Meanwhile, Menicon is strengthening its production capabilities for 1-DAY lenses at its facilities in Singapore and at the Kakamigahara plant in Japan.
While the company produced approximately 400 million 1-DAY lenses in FY2024, it plans to increase its production capacity by approximately 1.5 times through multi-site expansion. Subsequently, the company intends to further expand production to meet global demand.
Please refer to the attached document for more details on manufacturing site.

On the commencement of commercial production at the Malaysia Plant, President and CEO Koji Kawaiura commented:
“The launch of the Malaysia Plant marks a significant step forward in dramatically increasing our supply of 1-DAY lenses, a category experiencing rapidly growing demand worldwide. This new facility will enable us to accelerate strategic global partnerships that support our long-term growth.”

With the start of commercial production, Menicon will further strengthen its ability to deliver high‑quality products—rooted in Japanese craftsmanship and precision manufacturing, the company’s signature SMART TOUCH™ technology—to customers across Europe, North America, other global markets, and Japan.
As the global market for 1-DAY lenses continues to grow, Menicon aims to further enhance its presence and continue creating long‑term value for society by providing better vision to people around the world.


Contact details:

Menicon Co., Ltd. – Public Relations Department
Email: [email protected]

Media

More from this category

  • General News, Medical Health Aged Care
  • 12/03/2026
  • 14:07
Parliament of Australia

Public hearing concerning the National Redress Scheme

TheJoint Standing Committee on Implementation of the National Redress Schemewill hold a public hearing in Canberra on Friday, 13 March 2026, for itsinquiry into the continuing operation of the Scheme. Committee Chair, Ms Jodie Belyea MP, said the Committee is grateful for the contributions made in support of the inquiry to date. ‘The National Redress Scheme plays a central role in Australia’s response to institutional child sexual abuse. It is an important program for a significant number of people. The Committee has received a substantial number of submissions in support of our current inquiry, and public hearings over the coming…

  • Energy, Medical Health Aged Care
  • 12/03/2026
  • 12:11
Sweltering Cities

The cost of keeping cool is making Australians sick: New report reveals millions forced to ration cooling during record heat

12 March 2026 Sweltering Cities has today released the findings of its 2026 Summer Survey, exposing a national health crisis driven by the rising cost of keeping cool. With data from more than 2,600 respondents across 766 postcodes, the report proves that for many Australians the high cost of staying cool is having serious physical and mental health impacts. The 2025/26 summer saw 68% of all respondents report feeling unwell due to heat. However, the survey reveals that this burden is falling most heavily on those already struggling with the cost of living. For renters and people with disabilities, the…

  • Medical Health Aged Care
  • 12/03/2026
  • 10:01
Monash University

Monash Researchers Awarded up to $22.4 Million AUD to Develop New Medicines for Restoring Lymphatic Pumping

Monash University is partnering with the University of Missouri and the University of Pennsylvania to develop first-in-class medicines designed to reverse poor lymphatic vessel contraction and transport function, backed by an up to $22.4 million AUD Award from the Advanced Research Projects Agency for Health (ARPA-H). The researchers join ARPA-H’s GLIDE (Groundbreaking Lymphatic Interventions and Drug Exploration) program to transform how both primary lymphatic diseases and common chronic diseases are treated by developing innovative therapeutics that alleviate, repair or regenerate a dysfunctional lymphatic vascular system. Professor Arthur Christopoulos, Dean of the Faculty of Pharmacy and Pharmaceutical Sciences, said the work…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.